Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07508306Recruiting

Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical Morbidity

Role: lead

NCT07409779Not ApplicableNot Yet Recruiting

Capsular Distension Versus Corticosteroid Injection in Adhesive Capsulitis

Role: lead

NCT07475637Completed

Liquid Biopsy Monitoring Of EGFR T790M in Advanced Non-Small Cell Lung Cancer

Role: lead

NCT06850467Not ApplicableCompleted

Sexual Intercourse on Spontaneous Onset of Labor

Role: lead

NCT04915963Phase 3Completed

Vitamin D Supplementation in Intensive Care Unit Patients

Role: collaborator

NCT03863756Unknown

Performance of EOS Imaging System in the Assessment of Spondyloarthritis Structural Changes Compared With Standard Radiography

Role: lead

All 6 trials loaded